2016 VAM: 3306 - Using SCIT vs. SLIT to Modify Allergic Disease
This session will provide a cutting-edge perspective on the use of allergy immunotherapy, and its potential to modify disease natural history.
AMA PRA Category 1 Credits™: 1.25
CE: 1.25
Credit must be claimed by May 31, 2018. Any credit request on or after June 1, 2018 will be subject to an administrative fee.
Target Audience
Physicians
Allergists/Immunologists
Nurses
Nurse Practitioners
Allied Health Professionals
Learning Objectives
Upon completion of this activity, participants will be able to:
1. Discuss the latest data on the efficacy and safety of SCIT compared to SLIT for grass pollen allergy
2. Identify several newly discovered biomarkers for AIT efficacy
3. Discuss and explain safety and adherence issues of SLIT and SCIT and utilize resources to try to overcome them
Additional Information
Attachment | Size |
---|---|
2016 Annual Meeting Disclosures | 120.13 KB |
Prof. Stephen R. Durham, MA MD FRCP, NHLI Imperial College London, London
Prof. Giovanni Passalacqua, MD, IRCCS San Martino Hospital-IST-University of Genoa, Italy
Dr. Mohamed H. Shamji, PhD FAAAAI, Royal Brompton and Harefield Hospitals NHS Trust, London, United Kingdom
Available Credit
- 1.25 AttendanceAttendance credit.
- 1.25 CECE credit.
- 1.25 CMECME credit.